Skip to content
Screener

Discontinued — last reported Q2 '26

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Pfizer logo
PfizerPFE
-$248M-109%
Arrowhead Research logo
Arrowhead ResearchARWR
-$132.73M-136%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$78.4M+1,442%
ALN
Alnylam PharmaceuticalsALNY
$164.49M+348%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$92M+20.0%

Segments

By segment

See full
Ionis Operations-$114.65M-193%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Other income, net987102529569
Income (loss) before income tax benefit (expense)(113,382)123,531(205,692)(23,291)
Income tax benefit (expense)(1,264)20(1,482)(96)
Net income (loss)$$(114,646)$123,551$(207,174)(23,387)
Basic net income (loss) per share$$(0.69)$0.78$(1.25)(0.15)
Diluted net income (loss) per share$$(0.69)$0.70$(1.25)(0.15)
Shares used in computing basic net income (loss) per share165,419159,137165,148158,937
Shares used in computing diluted net income (loss) per share165,419182,331165,148158,937

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's net income?
Ionis Pharmaceuticals (IONS) reported net income of -$114.65M in Q2 2026.
How has Ionis Pharmaceuticals's net income changed year-over-year?
Ionis Pharmaceuticals's net income decreased by 192.8% year-over-year, from $123.55M to -$114.65M.
What is the long-term trend for Ionis Pharmaceuticals's net income?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's net income has grown at a 91.1% compound annual growth rate (CAGR), from -$28.6M to -$381.39M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Ionis Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude